GSK3368715 (Synonyms: EPZ019997) |
カタログ番号GC36191 |
GSK3368715 (EPZ019997) は、経口活性で可逆的な S-アデノシル-L-メチオニン (SAM) 非競合型 I 型タンパク質アルギニンメチルトランスフェラーゼ (PRMT) 阻害剤です (IC50=3.1 nM (PRMT1)、48 nM (PRMT3)、1148 nM ( PRMT4)、5.7 nM (PRMT6)、1.7 nM (PRMT8))。 GSK3368715 (EPZ019997) は、アルギニンのメチル化状態を変化させ、エクソンの使用を変更し、強力な抗がん活性を持っています。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1629013-22-4
Sample solution is provided at 25 µL, 10mM.
GSK3368715 (EPZ019997) is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50=3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)). GSK3368715 (EPZ019997) produces a shift in arginine methylation states, alters exon usage, and has strong anti-cancer activity[1]. IC50: 3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)[1]Kiapp: 1.5 nM (PRMT1), 81 nM (PRMT3), 19 nM (PRMT4), 2.4 nM (PRMT6), 2 nM (PRMT8)[1]
GSK3368715 (EPZ019997) shows 50% or more growth inhibition relative to DMSO-treated cells in the majority of 249 cancer cell lines, representing 12 tumor types[1].
GSK3368715 (EPZ019997) significantly effects on the growth of BxPC3 xenografts at all doses tested, reducing tumor growth by 78% and 97% in the 150- and 300-mg/kg dose groups, respectively[1].
[1]. Fedoriw A, et al. Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss. Cancer Cell. 2019 Jul 8;36(1):100-114.e25.
Average Rating: 5
(Based on Reviews and 36 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *